Healthcare company Beckman Coulter reported on Monday the receipt of Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) for its Access SARS-CoV-2 IgG antibody test.
SARS-CoV-2 is the virus that causes COVID-19.
Beckman Coulter has already shipped tests to more than 400 hospitals, clinics and diagnostics laboratories in the United States, and has begun distribution of the new antibody test globally to countries that accept the FDA EUA and CE Mark.
According to the company, the Access SARS-CoV-2 IgG test with 100% sensitivity and 99.6% specificity can also be run on its Access 2 analyzer, a compact table-top analyzer enabling high-quality serology testing to be carried out in small hospitals and clinics.
The test is claimed to be the only SARS-CoV-2 IgG assay which targets antibodies that recognize the receptor binding domain (RBD) of the spike protein which SARS-CoV-2 uses to bind to a human cell receptor. Many vaccine developers are targeting the RBD of the spike protein in their vaccine development.
Beckman Coulter will be seeking EUA for IL-6 and Access SARS-CoV-2 IgM in the near future.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine